Abstract: The present invention relates to a gel composition comprising taurodeoxycholic acid, its derivative, or a pharmaceutically acceptable salt thereof as an active ingredient, hyaluronic acid, its derivative, or a pharmaceutically acceptable salt thereof; and a surfactant that is polysorbate 20 or polysorbate 80, and a composition comprising the same for preventing or treating atopic dermatitis, and specifically, the composition has fewer side effects and higher therapeutic efficacy compared to existing atopic dermatitis treatments, it is effective and has a significantly superior effect compared to conventional formulations, and so it can be usefully used as a new pharmaceutical composition that can prevent or treat atopic dermatitis.

Abstract: The present invention relates to a composition for treating coronavirus infection-19 (COVID-19), comprising taurodeoxycholic acid (TDCA) or a pharmaceutically acceptable salt thereof and an antiviral agent as active ingredients, it was confirmed that clinical symptoms were cured in patients with COVID-19 pneumonia who were administered a combination of a pharmaceutically acceptable salt of taurodeoxycholic acid as an inflammasome inhibitor and an antiviral agent, and thus this combination of taurodeoxycholic acid (TDCA) or a pharmaceutically acceptable salt thereof as an inflammasome inhibitor and an antiviral agent, holds promise as active ingredients in compositions for the prevention or treatment of lower respiratory tract infectious diseases, including COVID-19.

Abstract: The present invention relates to a composition for the prevention or treatment of pulmonary fibrosis, comprising a pharmaceutically acceptable salt of taurodeoxycholic acid as an active ingredient. Specifically, it has been confirmed that administration of a pharmaceutically acceptable salt of taurodeoxycholic acid results in a reduction of pulmonary fibrosis and the expression of pulmonary fibrosis-related factors in both an idiopathic pulmonary fibrosis animal model and a pulmonary fibrosis cell model. Therefore, taurodeoxycholic acid or a pharmaceutically acceptable salt thereof can be utilized as an active ingredient in a composition for the prevention or treatment of pulmonary fibrosis.

Abstract: The present invention relates to a bispecific humanized single domain antibody targeting both PD-L1 and CD47, as well as uses thereof. Specifically, a humanized single domain antibody that binds bispecifically to PD-L1 and CD47, which are immune checkpoint proteins, has been developed, and its efficacy has been confirmed both in vitro and in vivo. Therefore, the bispecific humanized single domain antibody can be effectively used as an immune checkpoint inhibitor for immuno-oncology therapy.

Abstract: The present invention relates to a composition for preventing or treating virus infection diseases containing taurodeoxycholic acid or a pharmaceutically acceptable salt thereof as an active ingredient. Specifically, inflammatory cells and inflammatory cytokines were found to decrease in the lungs of an influenza virus-infected animal model to which taurodeoxycholic acid or a pharmaceutically acceptable salt thereof was administered as an inflammasome inhibitor, and thus the inflammasome inhibitor containing taurodeoxycholic acid or a pharmaceutically acceptable salt thereof can be used as an active ingredient in the composition for preventing or treating virus infection diseases.

Abstract: The present invention relates to a novel compound and a preparation method therefor. The compound according to the present invention exhibits inhibitory activity against the generation of TNF-? that is an inflammatory cytokine produced by inflammation initiation reaction, and against the generation of IL-1? by inflammasome activation, and thus, can be developed as a therapeutic agent for related inflammatory diseases.

Abstract: The present invention relates to a bispecific single domain antibody against PD-L1 and CD47 and uses thereof. Specifically, a single domain antibody that specifically binds to PD-L1 and CD47, immune checkpoint proteins, has been constructed, and its affinity for an immune antigen and antitumor effect have been verified, so the bispecific single domain antibody can be usefully used as an immune checkpoint inhibitor in cancer immunotherapy.

Abstract: The present invention relates to a single domain antibody against PD-L1 and uses thereof. Specifically, a single domain antibody that specifically binds to PD-L1, an immune checkpoint protein, has been constructed and its affinity for an immune antigen and antitumor effect have been verified, so the single domain antibody can be usefully used as an immune checkpoint inhibitor in cancer immunotherapy.

Abstract: The present invention relates to a single domain antibody against CD47 and uses thereof. Specifically, a single domain antibody that specifically binds to CD47, an immune checkpoint protein, has been constructed and its affinity for an immune antigen and antitumor effect have been verified, so the single domain antibody can be usefully used as an immune checkpoint inhibitor in cancer immunotherapy.

Abstract: The present invention relates to gene and cell therapy using a cell fusion technology and more particularly, cells overexpressing hemagglutinin neuraminidase (HN) and fusion (F) proteins have effects of enhancing cell fusion with other cells, restoring cell damage through the cell fusion with damaged cells, and transferring a normal gene. Therefore, when a vector including genes encoding the HN and F proteins of the present invention or a cell transformed with the vector is clinically applied to neurodegenerative diseases, muscular diseases, and the like, an effect of reducing the damage of damaged cells through cell fusion can be expected.

Abstract: The present invention relates to a bispecific single domain antibody against PD-L1 and CD47 and uses thereof. Specifically, a single domain antibody that specifically binds to PD-L1 and CD47, immune checkpoint proteins, has been constructed, and its affinity for an immune antigen and antitumor effect have been verified, so the bispecific single domain antibody can be usefully used as an immune checkpoint inhibitor in cancer immunotherapy.

Abstract: The present invention relates to a single domain antibody against PD-L1 and uses thereof. Specifically, a single domain antibody that specifically binds to PD-L1, an immune checkpoint protein, has been constructed and its affinity for an immune antigen and antitumor effect have been verified, so the single domain antibody can be usefully used as an immune checkpoint inhibitor in cancer immunotherapy.

Abstract: The present invention relates to a single domain antibody against CD47 and uses thereof. Specifically, a single domain antibody that specifically binds to CD47, an immune checkpoint protein, has been constructed and its affinity for an immune antigen and antitumor effect have been verified, so the single domain antibody can be usefully used as an immune checkpoint inhibitor in cancer immunotherapy.

Abstract: A gene and cell therapy using a cell fusion technology is proposed. Cells overexpressing hemagglutinin neuraminidase (HN) and fusion (F) proteins have effects of enhancing cell fusion with other cells, restoring cell damage through the cell fusion with damaged cells, and transferring a normal gene. Therefore, when a vector including genes encoding the HN and F proteins of the present invention or a cell transformed with the vector is clinically applied to neurodegenerative diseases, muscular diseases, and the like, an effect of reducing the damage of damaged cells through cell fusion can be expected.

Abstract: The present invention relates to a GPCR19-P2Xn receptor complex and use of the same, particularly to a method for screening a substance that regulates the interaction between GPCR19 and a P2Xn receptor in their complex; a method for screening a substance for prevention or treatment of an NLRP3 inflammasome-associated diseases utilizing the interaction between GPCR19 and a P2Xn receptor in their complex; and a method for preventing or treating an NLRP3 inflammasome-associated disease, which comprises administering to an individual a pharmaceutically effective amount of a substance that induces the interaction between GPCR19 and a P2Xn receptor in their complex.

Abstract: The present invention relates to a mass production method of sodium taurodeoxycholate having low impurity and few by-products, in which the procedure of process is simplified since isopropyl alcohol is used and separation and purification is performed through batch washing for commercial production of sodium taurodeoxycholate.

Abstract: The present invention relates to a composition for prevention or treatment of inflammatory bowel disease, which contains taurodeoxycholic acid or a pharmaceutically acceptable salt thereof as an active ingredient. Specifically, taurodeoxycholic acid and a pharmaceutically acceptable salt thereof can be used as an active ingredient of a composition for prevention or treatment of inflammatory bowel disease since it has been confirmed that the clinical symptoms and histopathological symptoms caused by inflammatory bowel disease are alleviated and the increase in inflammatory cells in bowels and the production of pro-inflammatory cytokines are suppressed by using a salt of taurodeoxycholic acid.

Abstract: The present invention relates to gene and cell therapy using a cell fusion technology and more particularly, cells overexpressing hemagglutinin neuraminidase (HN) and fusion (F) proteins have effects of enhancing cell fusion with other cells, restoring cell damage through the cell fusion with damaged cells, and transferring a normal gene. Therefore, when a vector including genes encoding the HN and F proteins of the present invention or a cell transformed with the vector is clinically applied to neurodegenerative diseases, muscular diseases, and the like, an effect of reducing the damage of damaged cells through cell fusion can be expected.

Abstract: The present invention relates to gene and cell therapy using a cell fusion technology and more particularly, cells overexpressing hemagglutinin neuraminidase (HN) and fusion (F) proteins have effects of enhancing cell fusion with other cells, restoring cell damage through the cell fusion with damaged cells, and transferring a normal gene. Therefore, when a vector including genes encoding the HN and F proteins of the present invention or a cell transformed with the vector is clinically applied to neurodegenerative diseases, muscular diseases, and the like, an effect of reducing the damage of damaged cells through cell fusion can be expected.

Abstract: The present invention relates to a method for inhibiting myeloid-derived suppressor cells or treating cancer comprising administering a pharmaceutical composition containing decitabine or its pharmaceutically acceptable salt as an active ingredient. The decitabine suppresses creation of a cell population of myeloid-derived suppressor cells (MDSC) created in spleen and bone marrow in tumorigenic mice and induces apoptosis of the MDSC cell population. Therefore, the decitabine may be useful as agents for treating MDSC-related diseases and anticancer immunotherapy, or an anticancer supplement.